Unibest

Pharmaceutical intermediates

Rucaparib Intermediates

2 pharmaceutical intermediates for Rucaparib. Indication: Prostate cancer; Ovarian cancer; Fallopian tube carcinoma; Peritoneal carcinoma; Ovarian cancer.

提交项目All intermediates

About Rucaparib

Originator
Clovis Oncology Inc
Indication
Prostate cancer; Ovarian cancer; Fallopian tube carcinoma; Peritoneal carcinoma; Ovarian cancer
Approved Date
12/19/2016
DS/DP
08/12/2027

Available intermediates

2 intermediates currently listed for Rucaparib. Request specifications, documentation or a quotation for any item below.

Rucaparib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Methyl 6-fluoro-1H-indole-4-carboxylate1082040-43-4//
8-Fluoro-1,3,4,5-tetrahydro-6H-pyrrolo[4,3,2-ef][2]benzazepin -6- one1408282-26-7//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenib

Building toward Rucaparib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →